The global T cell surface glycoprotein CD3 epsilon chain market is expected to grow at a CAGR of 5.5% during the forecast period, from 2021 to 2030. The growth of this market can be attributed to the increasing prevalence of autoimmune disorders and cancer, which are major drivers for the growth of this market. The increasing prevalence of these diseases is due to factors such as unhealthy lifestyle and environmental pollution.
The global T cell surface glycoprotein CD3 epsilon chain market has been segmented on the basis of type, application, and region. On the basis of type, it has been segmented into N007 (Novartis), Foralumab (BMS), Coltelizumab (Genentech), AV002 (AstraZeneca). On the basis of application, it has been segmented into autoimmune disorders, hepatitis B virus infection, multiple sclerosis disease process in adults with relapsing-remitting course or secondary progressive course who have not responded adequately to other therapies or who are intolerant to other therapies; prostate cancer; others including chronic lymphocytic leukemia/small lymphocytic lymphoma; myelodysplastic syndromes; systemic lupus erythematosus/lupus nephritis; psoriasis vulgaris/chronic plaque psoriasis in adults with moderate-to-severe plaque psoriasis who have not responded adequately to other therapies or who are intolerant to other therapies. On the basis for region it has been segmented into North America (US & Canada), Latin America (Mexico & Brazil), Europe (Germany & France) Asia Pacific excluding Japan(APeJ) and Middle East & Africa(MEA).
Some Of The Growth Factors Of This Market:
- Increasing prevalence of chronic diseases such as cancer, diabetes, and cardiovascular diseases is driving the growth of the T Cell Surface Glycoprotein CD3 Epsilon Chain market.
- Increasing awareness about T Cell Surface Glycoprotein CD3 Epsilon Chain among patients and healthcare professionals is also driving the growth of this market.
- The increasing number of clinical trials for new drugs in various therapeutic areas is also driving the growth of this market.
- The availability and affordability of generic drugs are some other factors that are contributing to the growth of this market.
Industry Growth Insights published a new data on “T Cell Surface Glycoprotein CD3 Epsilon Chain Market”. The research report is titled “T Cell Surface Glycoprotein CD3 Epsilon Chain Market research by Types (ND-007, Foralumab, Coltelizumab, AVA-002, Others), By Applications (Autoimmune Disorders, Hepatitis B, Multiple Sclerosis, Prostate Cancer, Others), By Players/Companies Amgen Inc, Celgene Corp, F. Hoffmann-La Roche Ltd, GlaxoSmithKline Plc, MacroGenics Inc, Meridigen Biotech Co Ltd, Numab Innovation AG, SYNIMMUNE GmbH, Tiziana Life Sciences Plc”.
Scope Of The Report
Report Attributes
Report Details
Report Title
T Cell Surface Glycoprotein CD3 Epsilon Chain Market Research Report
By Type
ND-007, Foralumab, Coltelizumab, AVA-002, Others
By Application
Autoimmune Disorders, Hepatitis B, Multiple Sclerosis, Prostate Cancer, Others
By Companies
Amgen Inc, Celgene Corp, F. Hoffmann-La Roche Ltd, GlaxoSmithKline Plc, MacroGenics Inc, Meridigen Biotech Co Ltd, Numab Innovation AG, SYNIMMUNE GmbH, Tiziana Life Sciences Plc
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
230
Number of Tables & Figures
161
Customization Available
Yes, the report can be customized as per your need.
Global T Cell Surface Glycoprotein CD3 Epsilon Chain Market Report Segments:
The global T Cell Surface Glycoprotein CD3 Epsilon Chain market is segmented on the basis of:
Types
ND-007, Foralumab, Coltelizumab, AVA-002, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Autoimmune Disorders, Hepatitis B, Multiple Sclerosis, Prostate Cancer, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Amgen Inc
- Celgene Corp
- F. Hoffmann-La Roche Ltd
- GlaxoSmithKline Plc
- MacroGenics Inc
- Meridigen Biotech Co Ltd
- Numab Innovation AG
- SYNIMMUNE GmbH
- Tiziana Life Sciences Plc
Highlights of The T Cell Surface Glycoprotein CD3 Epsilon Chain Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- ND-007
- Foralumab
- Coltelizumab
- AVA-002
- Others
- By Application:
- Autoimmune Disorders
- Hepatitis B
- Multiple Sclerosis
- Prostate Cancer
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the T Cell Surface Glycoprotein CD3 Epsilon Chain Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
The T Cell Surface Glycoprotein CD3 Epsilon Chain is a protein that is found on the surface of some T cells. This protein helps to bind to other proteins and cells, and it also plays a role in the immune system's ability to fight off infections.
Some of the key players operating in the t cell surface glycoprotein cd3 epsilon chain market are Amgen Inc, Celgene Corp, F. Hoffmann-La Roche Ltd, GlaxoSmithKline Plc, MacroGenics Inc, Meridigen Biotech Co Ltd, Numab Innovation AG, SYNIMMUNE GmbH, Tiziana Life Sciences Plc.
The t cell surface glycoprotein cd3 epsilon chain market is expected to grow at a compound annual growth rate of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. T Cell Surface Glycoprotein CD3 Epsilon Chain Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. T Cell Surface Glycoprotein CD3 Epsilon Chain Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. T Cell Surface Glycoprotein CD3 Epsilon Chain Market - Supply Chain
4.5. Global T Cell Surface Glycoprotein CD3 Epsilon Chain Market Forecast
4.5.1. T Cell Surface Glycoprotein CD3 Epsilon Chain Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. T Cell Surface Glycoprotein CD3 Epsilon Chain Market Size (000 Units) and Y-o-Y Growth
4.5.3. T Cell Surface Glycoprotein CD3 Epsilon Chain Market Absolute $ Opportunity
5. Global T Cell Surface Glycoprotein CD3 Epsilon Chain Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. T Cell Surface Glycoprotein CD3 Epsilon Chain Market Size and Volume Forecast by Type
5.3.1. ND-007
5.3.2. Foralumab
5.3.3. Coltelizumab
5.3.4. AVA-002
5.3.5. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global T Cell Surface Glycoprotein CD3 Epsilon Chain Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. T Cell Surface Glycoprotein CD3 Epsilon Chain Market Size and Volume Forecast by Application
6.3.1. Autoimmune Disorders
6.3.2. Hepatitis B
6.3.3. Multiple Sclerosis
6.3.4. Prostate Cancer
6.3.5. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global T Cell Surface Glycoprotein CD3 Epsilon Chain Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. T Cell Surface Glycoprotein CD3 Epsilon Chain Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global T Cell Surface Glycoprotein CD3 Epsilon Chain Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. T Cell Surface Glycoprotein CD3 Epsilon Chain Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global T Cell Surface Glycoprotein CD3 Epsilon Chain Demand Share Forecast, 2019-2026
9. North America T Cell Surface Glycoprotein CD3 Epsilon Chain Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America T Cell Surface Glycoprotein CD3 Epsilon Chain Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America T Cell Surface Glycoprotein CD3 Epsilon Chain Market Size and Volume Forecast by Application
9.4.1. Autoimmune Disorders
9.4.2. Hepatitis B
9.4.3. Multiple Sclerosis
9.4.4. Prostate Cancer
9.4.5. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America T Cell Surface Glycoprotein CD3 Epsilon Chain Market Size and Volume Forecast by Type
9.7.1. ND-007
9.7.2. Foralumab
9.7.3. Coltelizumab
9.7.4. AVA-002
9.7.5. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America T Cell Surface Glycoprotein CD3 Epsilon Chain Demand Share Forecast, 2019-2026
10. Latin America T Cell Surface Glycoprotein CD3 Epsilon Chain Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America T Cell Surface Glycoprotein CD3 Epsilon Chain Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America T Cell Surface Glycoprotein CD3 Epsilon Chain Market Size and Volume Forecast by Application
10.4.1. Autoimmune Disorders
10.4.2. Hepatitis B
10.4.3. Multiple Sclerosis
10.4.4. Prostate Cancer
10.4.5. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America T Cell Surface Glycoprotein CD3 Epsilon Chain Market Size and Volume Forecast by Type
10.7.1. ND-007
10.7.2. Foralumab
10.7.3. Coltelizumab
10.7.4. AVA-002
10.7.5. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America T Cell Surface Glycoprotein CD3 Epsilon Chain Demand Share Forecast, 2019-2026
11. Europe T Cell Surface Glycoprotein CD3 Epsilon Chain Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe T Cell Surface Glycoprotein CD3 Epsilon Chain Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe T Cell Surface Glycoprotein CD3 Epsilon Chain Market Size and Volume Forecast by Application
11.4.1. Autoimmune Disorders
11.4.2. Hepatitis B
11.4.3. Multiple Sclerosis
11.4.4. Prostate Cancer
11.4.5. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe T Cell Surfae Glycoprotein CD3 Epsilon Chain Market Size and Volume Forecast by Type
11.7.1. ND-007
11.7.2. Foralumab
11.7.3. Coltelizumab
11.7.4. AVA-002
11.7.5. Others
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe T Cell Surface Glycoprotein CD3 Epsilon Chain Demand Share, 2019-2026
12. Asia Pacific T Cell Surface Glycoprotein CD3 Epsilon Chain Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific T Cell Surface Glycoprotein CD3 Epsilon Chain Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific T Cell Surface Glycoprotein CD3 Epsilon Chain Market Size and Volume Forecast by Application
12.4.1. Autoimmune Disorders
12.4.2. Hepatitis B
12.4.3. Multiple Sclerosis
12.4.4. Prostate Cancer
12.4.5. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific T Cell Surface Glycoprotein CD3 Epsilon Chain Market Size and Volume Forecast by Type
12.7.1. ND-007
12.7.2. Foralumab
12.7.3. Coltelizumab
12.7.4. AVA-002
12.7.5. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific T Cell Surface Glycoprotein CD3 Epsilon Chain Demand Share, 2019-2026
13. Middle East & Africa T Cell Surface Glycoprotein CD3 Epsilon Chain Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa T Cell Surface Glycoprotein CD3 Epsilon Chain Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa T Cell Surface Glycoprotein CD3 Epsilon Chain Market Size and Volume Forecast by Application
13.4.1. Autoimmune Disorders
13.4.2. Hepatitis B
13.4.3. Multiple Sclerosis
13.4.4. Prostate Cancer
13.4.5. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa T Cell Surface Glycoprotein CD3 Epsilon Chain Market Size and Volume Forecast by Type
13.7.1. ND-007
13.7.2. Foralumab
13.7.3. Coltelizumab
13.7.4. AVA-002
13.7.5. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa T Cell Surface Glycoprotein CD3 Epsilon Chain Demand Share, 2019-2026
14. Competition Landscape
14.1. Global T Cell Surface Glycoprotein CD3 Epsilon Chain Market: Market Share Analysis
14.2. T Cell Surface Glycoprotein CD3 Epsilon Chain Distributors and Customers
14.3. T Cell Surface Glycoprotein CD3 Epsilon Chain Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Amgen Inc
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Celgene Corp
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. F. Hoffmann-La Roche Ltd
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. GlaxoSmithKline Plc
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. MacroGenics Inc
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Meridigen Biotech Co Ltd
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Numab Innovation AG
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. SYNIMMUNE GmbH
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Tiziana Life Sciences Plc
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
